[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201190208A1 - Соединения для лечения метаболических расстройств - Google Patents

Соединения для лечения метаболических расстройств

Info

Publication number
EA201190208A1
EA201190208A1 EA201190208A EA201190208A EA201190208A1 EA 201190208 A1 EA201190208 A1 EA 201190208A1 EA 201190208 A EA201190208 A EA 201190208A EA 201190208 A EA201190208 A EA 201190208A EA 201190208 A1 EA201190208 A1 EA 201190208A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
metabolic disorders
connections
diabetes
possess
Prior art date
Application number
EA201190208A
Other languages
English (en)
Inventor
Оскар Барба
Питер Тимоти Фрай
Мэттью Колин Тор Файф
Уилльям Гэттрелл
Ревати Перпетуа Дживаратнам
Томас Мартин Крулле
Мартин Джеймс Проктер
Колин Питер Сэмбрук-Смит
Карен Лесли Скофилд
Дональд Смит
Алан Джон Уилльям Стюарт
Дэвид Френч Стоунхаус
Саймон Эндрю Суэйн
Original Assignee
Прозидион Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Прозидион Лимитед filed Critical Прозидион Лимитед
Publication of EA201190208A1 publication Critical patent/EA201190208A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Изобретение относится к терапевтическим соединениям, которые обладают активностью агонистов GPR119 (сопряженный с G-белком рецептор 119) и полезны для лечения метаболических расстройств, включая диабет типа II.
EA201190208A 2009-03-12 2010-03-12 Соединения для лечения метаболических расстройств EA201190208A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0904284.7A GB0904284D0 (en) 2009-03-12 2009-03-12 Compounds for the treatment of metabolic disorders
PCT/GB2010/050440 WO2010103333A1 (en) 2009-03-12 2010-03-12 Compounds for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
EA201190208A1 true EA201190208A1 (ru) 2012-04-30

Family

ID=40600945

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201190208A EA201190208A1 (ru) 2009-03-12 2010-03-12 Соединения для лечения метаболических расстройств

Country Status (18)

Country Link
US (1) US20120077793A1 (ru)
EP (1) EP2406247A1 (ru)
JP (1) JP2012520282A (ru)
KR (1) KR20110133044A (ru)
CN (1) CN102348703A (ru)
AU (1) AU2010222671A1 (ru)
BR (1) BRPI1013245A2 (ru)
CA (1) CA2754709A1 (ru)
CL (1) CL2011002181A1 (ru)
EA (1) EA201190208A1 (ru)
GB (1) GB0904284D0 (ru)
IL (1) IL215049A0 (ru)
MA (1) MA33190B1 (ru)
MX (1) MX2011009490A (ru)
PE (1) PE20120657A1 (ru)
SG (1) SG174279A1 (ru)
WO (1) WO2010103333A1 (ru)
ZA (1) ZA201107445B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102803214A (zh) 2009-06-24 2012-11-28 贝林格尔.英格海姆国际有限公司 新化合物、与之相关的药物组合物和方法
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
US8853239B2 (en) * 2011-12-09 2014-10-07 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
AR091739A1 (es) 2012-07-11 2015-02-25 Elcelyx Therapeutics Inc Composiciones y metodos para reducir el riesgo cardiometabolico
KR101719321B1 (ko) * 2016-03-31 2017-03-23 충남대학교산학협력단 3-(4-클로로페닐)벤조[4, 5]이미다조[2, 1-b]싸이아졸-6-카복실산을 포함하는 항비만 또는 항우울증 치료용 조성물
CN109053524A (zh) * 2018-09-11 2018-12-21 山东谛爱生物技术有限公司 一种N-Boc-3-羟基氮杂环丁烷的制备方法
WO2023208081A1 (en) * 2022-04-28 2023-11-02 Shenzhen Bay Laboratory Substituted fluorosulfate and use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100042A (en) 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
GB9719496D0 (en) 1997-09-13 1997-11-19 Glaxo Group Ltd G protien chimeras
EP1123391A2 (en) 1998-09-01 2001-08-16 BASF Aktiengesellschaft Methods for improving the function of heterologous g protein-coupled receptors
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
JP4413863B2 (ja) * 2002-11-07 2010-02-10 メルク エンド カムパニー インコーポレーテッド 糖尿病の治療又は予防のためのジペチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体
WO2005061489A1 (en) 2003-12-24 2005-07-07 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
CA2591922A1 (en) 2004-12-24 2006-06-29 Prosidion Limited G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
WO2006067532A1 (en) 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor agonists
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
KR20080025190A (ko) 2005-06-30 2008-03-19 프로시디온 리미티드 G-단백질 결합된 수용체 효능제
JP5114395B2 (ja) * 2005-06-30 2013-01-09 プロシディオン・リミテッド Gpcrアゴニスト
EP1907384A2 (en) 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
EP2308840A1 (en) 2005-06-30 2011-04-13 Prosidion Limited GPCR agonists
AU2007235673A1 (en) 2006-04-06 2007-10-18 Prosidion Limited Heterocyclic GPCR agonists
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
GB0610746D0 (en) 2006-06-01 2006-07-12 Prosidion Ltd Method of treatment
WO2008070692A2 (en) * 2006-12-06 2008-06-12 Smithkline Beecham Corporation Bicyclic compounds and use as antidiabetics
CL2008000017A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
US20100048625A1 (en) 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine gpcr agonists
PE20081659A1 (es) 2007-01-04 2008-10-24 Prosidion Ltd Agonistas de gpcr
WO2008081204A1 (en) 2007-01-04 2008-07-10 Prosidion Limited Piperidine gpcr agonists
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
JP2010539152A (ja) 2007-09-10 2010-12-16 プロシディオン・リミテッド 代謝障害の治療のための化合物
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
US8568899B2 (en) 2007-10-18 2013-10-29 Jx Nippon Mining & Metals Corporation Metal covered polyimide composite, process for producing the composite, and process for producing electronic circuit board
CN101621337B (zh) 2008-06-30 2013-08-07 华为技术有限公司 一种时延调节装置与方法
CA2728042A1 (en) 2008-07-10 2010-01-14 Prosidion Limited Piperidinyl gpcr agonists
WO2010004344A1 (en) 2008-07-10 2010-01-14 Prosidion Limited Piperidine gpcr agonists
GB0812641D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds

Also Published As

Publication number Publication date
PE20120657A1 (es) 2012-06-27
CA2754709A1 (en) 2010-09-16
ZA201107445B (en) 2012-06-27
WO2010103333A1 (en) 2010-09-16
MA33190B1 (fr) 2012-04-02
CN102348703A (zh) 2012-02-08
JP2012520282A (ja) 2012-09-06
KR20110133044A (ko) 2011-12-09
MX2011009490A (es) 2011-10-11
US20120077793A1 (en) 2012-03-29
BRPI1013245A2 (pt) 2016-04-05
SG174279A1 (en) 2011-10-28
AU2010222671A1 (en) 2011-11-03
EP2406247A1 (en) 2012-01-18
GB0904284D0 (en) 2009-04-22
CL2011002181A1 (es) 2012-05-04
IL215049A0 (en) 2011-11-30

Similar Documents

Publication Publication Date Title
EA201190209A1 (ru) Соединения для лечения метаболических расстройств
EA201190208A1 (ru) Соединения для лечения метаболических расстройств
EA201190207A1 (ru) Соединения для лечения метаболических расстройств
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201101524A1 (ru) Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA200870424A1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
TR201819564T4 (tr) Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar.
MA32975B1 (fr) Antagonistes de c5ar
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201001253A1 (ru) N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201270767A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов
EA200970835A1 (ru) Индазолы, применяемые для лечения расстройств, опосредуемых эстрогеновым рецептором бета
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
CL2008002111A1 (es) Compuestos derivados de piridona, agonistas del receptor acoplado a proteina g gpr119; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico, cancer, entre otras.
EA201200975A1 (ru) Тиено[2,3-b]пиридиндионовые активаторы амфк и их терапевтическое применение
MX2009011358A (es) Derivados de pirimidinona y metodos para su uso.
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200970303A1 (ru) Тиазолпиразолопиримидин в качестве антагониста рецептора крф1